KTWO // K2 Capital Acquisition Corporation Class A Ordinary Share
ANR <GO> NASDAQ RQD COCKPIT → CIK 0002086524 ↗ Health Care • Medical/Dental Instruments
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$8
MEDIAN
$11
MEAN
$12
HIGH
$14
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE KTWO TAPE
KTWO // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $12.23 | $11.63 | 2025-02-14 | $9.20 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $12.74 | $11.93 | 2025-02-06 | $9.50 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $11.53 | $11.12 | 2025-01-29 | $9.71 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $10.31 | — | 2025-01-17 | $9.91 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $8.90 | $9.60 | 2025-01-09 | $9.00 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $12.03 | $10.51 | 2024-12-18 | $8.80 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $9.81 | $10.21 | 2024-12-04 | $9.40 | -4.3% | 48% | C |